In this regard, AHF patients with renal dysfunction whose circulating GAS6 levels may indicate a primary inflammatory/fibrotic susceptibility may benefit from optimization of anti-inflammatory/antifibrosis therapies, such as mineralcorticoid receptor antagonists. The gene discussed is GAS6; the disease is Abnormal renal physiology.